Two heart survivors reunite with life-saving doctors June 20 at Ochsner Lafayette General to celebrate advanced care and ...

The following is a summary of “Endocrine response in cardiogenic shock complicating myocardial infarction: the prognostic value of growth hormone and IGF-1,” published in the May 2025 issue of Journal ...

Objective We investigated the benefit of Impella, a modern percutaneous mechanical support (pMCS) device, versus former standard intra-aortic balloon pump (IABP) in acute myocardial infarction ...

The Impella device (Impella, Abiomed, Danvers, MA) is a percutaneous transvalvular microaxial flow pump that is currently used for (1) cardiogenic shock, (2) left ventricular unloading (combination of ...

gHeart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, and Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain ...

Female shock patients face delays in treatment and are less likely to receive approved interventions, says Suzanne Baron.

The purpose of this study is to assess renal recovery after Impella 5.5 placement in patients with cardiogenic shock assessed by an increase in glomerular filtration rate, and a decrease in serum ...

In the last year or so, we’ve seen a randomised trial that was positive in cardiogenic shock with Impella. How has that changed things, and how are we going to need to adapt? Dr Zaphiriou: I work in a ...

Background Despite no evidence of survival benefit, inotropes and vasopressors continue to be routinely used in the setting of acute myocardial infarction with cardiogenic shock (CS). ESC recommends ...

CardioVascular Center, Tufts Medical Center, Boston, MA (S.L.H., K.E., N.K.K.). Faculty of Health and Medicine, University of New South Wales, Sydney, Australia (S.L.H.).

The Impella 5.5 delivers full cardiac support ... patients advanced mechanical circulatory support for treating cardiogenic shock,” said Luke Seibolt, MD, interventional cardiologist at SGMC ...